The installation consists of a training and an integration phase. The initial non-commercial phase is limited to one month and will then, if approved by the hospital administration, enter the commercial phase. If approved the signed agreement will amount to a minimum consumption of kits equal to EUR 70,000 per year.

The Chhatrapati Shivaji Subharti Hospital & Medical College has 1000 beds and handles more than 400 cancer patients monthly. The hospital is strongly dedicated to cancer care and Oncology and treats more than 40 head- & neck cancer patients per month.

"We are delighted to add our second University hospital in India to the list of Hospitals that chose to partner with us and sees the potential the non-destructive approach of treating cancer that TSE can offer today. We are looking forward to starting the integration process in the beginning of April." says Mohan Frick CEO at ChemoTech.

For further information please contact:

Mohan Frick, CEO

Phone: +46 (0)10-218 93 00

E-mail: ir@chemotech.se

Scandinavian ChemoTech AB (publ)

ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Redeye AB is the company's Certified Adviser. Read more at: www.chemotech.se.